93 related articles for article (PubMed ID: 21170924)
1. Flavonoids inhibit angiogenic cytokine production by human glioma cells.
Freitas S; Costa S; Azevedo C; Carvalho G; Freire S; Barbosa P; Velozo E; Schaer R; Tardy M; Meyer R; Nascimento I
Phytother Res; 2011 Jun; 25(6):916-21. PubMed ID: 21170924
[TBL] [Abstract][Full Text] [Related]
2. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
3. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory and anti-angiogenic effects of flavonoids isolated from Lycium barbarum Linnaeus on human umbilical vein endothelial cells.
Wu WB; Hung DK; Chang FW; Ong ET; Chen BH
Food Funct; 2012 Oct; 3(10):1068-81. PubMed ID: 22751795
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study.
Costa R; Carneiro A; Rocha A; Pirraco A; Falcão M; Vasques L; Soares R
J Cell Biochem; 2009 Dec; 108(6):1410-7. PubMed ID: 19859900
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors.
Zhang J; Jia Z; Li Q; Wang L; Rashid A; Zhu Z; Evans DB; Vauthey JN; Xie K; Yao JC
Cancer; 2007 Apr; 109(8):1478-86. PubMed ID: 17340592
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity.
Fujiwara M; Muragaki Y; Ooshima A
Arch Dermatol Res; 2005 Oct; 297(4):161-9. PubMed ID: 16184401
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells.
Moreno MJ; Ball M; Andrade MF; McDermid A; Stanimirovic DB
Glia; 2006 Jun; 53(8):845-57. PubMed ID: 16586492
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic activity of Ipomoea obscura extract and Ipobscurine-A.
Hamsa TP; Kuttan G
Immunopharmacol Immunotoxicol; 2011 Sep; 33(3):488-97. PubMed ID: 21058930
[TBL] [Abstract][Full Text] [Related]
13. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
Barzelay A; Lowenstein A; George J; Barak A
Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
16. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis.
Ricci AG; Olivares CN; Bilotas MA; Meresman GF; Barañao RI
Reprod Sci; 2011 Jul; 18(7):614-22. PubMed ID: 21266664
[TBL] [Abstract][Full Text] [Related]
17. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in high-grade gliomas: past, present, and future.
Curry RC; Dahiya S; Alva Venur V; Raizer JJ; Ahluwalia MS
Expert Rev Anticancer Ther; 2015 Apr; 15(4):387-97. PubMed ID: 25797685
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
20. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]